Genmab — Januar 2021
-
En knap 1 år gammel artikel fra Børsen, meget er selvfølgelig ændret allerede kursmæssigt
, men interessant alligevel: https://penge.borsen.dk/nyheder/penge/article1978204.ece -
God morgen.
-
Medstifter af Genmab: "Industrien står enormt stærkt som følge af virussen, og det er ikke forbi"
Florian Schönharting er medstifter af biotekselskabet Genmab og har i en årrække været succesrig biotekinvestor.
(medwatch.dk)
-
JP Morgan har Novo som top-pick for 2021 - de nævner decideret data read out på MIM8 som en potentiel kursdriver for Novo, der oven i købet forstærker selskabets væksprofil.
-
Er der nogen, der har en ide om, hvornår vi kan se data? Jvf clinicaltrials har fase 2 været igang i præcist et år og behandlingscyklus er 26 uger - https://clinicaltrials.gov/ct2/show/NCT04204408
-
we know that at Q3 20 Novo said: Regarding the FVIII-mimicking antibody project, Mim8, we have despite a COVID-19 related period of delay in phase 1, caught up with the timelines and are now in phase 2 in hemophilia patients with or without inhibitors, hemophilia A patients.
-
Have we had any indications of the royalty rate and milestone payments?
-
Regulatory and sales milestones up to 250M $ according to this https://ir.genmab.com/news-releases/news-release-details/genmab-enters-commercial-license-agreement-novo-nordisk-duobody/
-
Single digit royalties
-
JPM expects data during 2021 - any indications when?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind